CS
EW icon

Credit Suisse’s Edwards Lifesciences EW Stock Holding History

Credit Suisse’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-13,800
Closed -$1.26M – 4365
2020
Q4 		$1.26M Buy
+13,800
New +$1.14M ﹤0.01% 3164

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Credit Suisse's EW Position: Q1 2024 in Review

Credit Suisse increased its Edwards Lifesciences (EW) stake by 2% in Q1 2024, buying an estimated $2.63M and bringing the position to 1,615,396 shares worth $154M. The position accounts for 0.15% of the portfolio, ranked #120.

Credit Suisse first reported a position in EW in Q2 2013 and has held it in 44 quarters since. The position peaked at $202M in Q4 2021. 1,279 funds tracked by Wall St. Rank hold EW as of Q1 2024.

  • Credit Suisse held 1,615,396 shares of Edwards Lifesciences worth $154M as of Q1 2024.
  • Credit Suisse bought 31,334 Edwards Lifesciences shares in Q1 2024, an estimated $2.63M.
  • Edwards Lifesciences made up 0.15% of Credit Suisse's portfolio in Q1 2024, its #120 holding.
  • Credit Suisse first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 44 quarters since.
  • Credit Suisse's Edwards Lifesciences position peaked at $202M in Q4 2021.
  • 1,279 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.